Gastric Cancer

, Volume 22, Issue 1, pp 237–243 | Cite as

Changes in bone metabolism after gastric cancer surgery in male patients: a prospective observational study

  • Yosuke AtsumiEmail author
  • Yasushi Rino
  • Hiroo Wada
  • Yuichi Kitani
  • Yukihiro Ozawa
  • Toru Aoyama
  • Takashi Oshima
  • Norio Yukawa
  • Takaki Yoshikawa
  • Munetaka Masuda
Original Article



Several retrospective studies have shown that bone disorders occur after gastric cancer surgery. This study was designed to prospectively evaluate the changes in bone metabolism after gastrectomy for gastric cancer.


We prospectively enrolled 39 men with early gastric cancer who underwent gastrectomy. We excluded women to avoid the effects of menopause. We employed dual energy X-ray absorptiometry (DEXA) to measure bone mineral density (BMD) of the lumbar spine. DEXA was performed before and 1 and 2 years after surgery. The serum levels of alkaline phosphatase (ALP), 1,25-dihydroxy vitamin D [1,25(OH)2VD], 25-hydroxy vitamin D [25(OH)VD], and estradiol were measured before surgery and every 3 months until 2 years after surgery.


DEXA revealed that BMD significantly decreased by 0.036 ± 0.033 g/cm2 12 months after gastrectomy (P < 0.001) and by 0.046 ± 0.040 g/cm2 24 months after gastrectomy (P < 0.001). The serum ALP level significantly increased by 38.31 ± 103.8 IU/L 24 months after surgery (P = 0.013). The serum 25(OH)VD level significantly decreased by 4.88 ± 6.42 ng/ml 24 months after surgery (P < 0.001), whereas the serum 1,25(OH)2VD levels were consistently in the normal range. The serum estradiol level significantly increased by 2.94 ± 7.49 pg/ml 12 months after gastrectomy (P = 0.035). A lower preoperative body mass index (BMI) significantly correlated with the reduction in BMD 12 months after surgery; the correlation coefficient was 0.37 (P = 0.025).


This study showed that a significant decrease in BMD was observed for up to 24 months after gastrectomy, not only 12 months.


Gastrectomy Bone mineral density T score Osteoporosis 



This study was funded by the Ministry of Education, Culture, Sports, Science and Technology of Japan, which provided Grants-in-aid for Scientific Research, the Japan Society for the Promotion of Science (19591553).

Compliance with ethical standards

Conflict of interest

We are indebted to the following organizations for providing funding for this study: Daiichi Sankyo, Inc., Tsumura & Co., Johnson and Johnson, Taiho Pharmaceutical Co., Ltd., Covidien Japan, Inc., Asahi Kasei Pharma Corporation, Kyowa Hakko Kirin Co. Ltd., and Yakult Honsha Co., Ltd..

Human rights statement

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.

Informed consent

Informed consent was obtained from all patients for being included in the study.


  1. 1.
    Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990–2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3:524–48.CrossRefGoogle Scholar
  2. 2.
    Sano T, Sasako M, Kinoshita T, Maruyama K. Recurrence of early gastric cancer. Follow-up of 1475 patients and review of the Japanese literature. Cancer. 1993;72:3174–8.CrossRefGoogle Scholar
  3. 3.
    Sarasin C. Osteomalacie and hypochrome aneaemie nach magenresektion. Gastroenterology. 1941;66:182–97.CrossRefGoogle Scholar
  4. 4.
    Inoue K, Shiomi K, Higashide S, Kan N, Nio Y, Tobe T, et al. Metabolic bone disease following gastrectomy: assessment by dual energy X-ray absorptiometry. Br J Surg. 1992;79:321–4.CrossRefGoogle Scholar
  5. 5.
    Kobayashi S, Takahashi C, Kuroda T, Sugenoya A, Iida F, Katoh K. Calcium regulating hormones and bone mineral content in patients after subtotal gastrectomy. Surg Today. 1994;24:295–8.CrossRefGoogle Scholar
  6. 6.
    Liedman B, Bosaeus I, Mellstrom D, Lundell L. Osteoporosis after total gastrectomy. Results of a prospective, clinical study. Scand J Gastroenterol. 1997;32:1090–5.CrossRefGoogle Scholar
  7. 7.
    Mellstrom D, Johansson C, Johnell O, Lindstedt G, Lundberg PA, Obrant K, et al. Osteoporosis, metabolic aberrations, and increased risk for vertebral fractures after partial gastrectomy. Calcified Tissue Int. 1993;53:370–7.Google Scholar
  8. 8.
    Nishimura O, Furumoto T, Nosaka K, Kouno K, Sumikawa M, Hisaki T, et al. Bone disorder following partial and total gastrectomy with reference to bone mineral content. Jpn J Surg. 1986;16:98–105.CrossRefGoogle Scholar
  9. 9.
    Rino Y, Takanashi Y, Yamamoto Y, Inagaki D, Kawamoto M, Harada H, et al. Bone disorder and vitamin D after gastric cancer surgery. Hepato-gastroenterology. 2007;54:1596–600.Google Scholar
  10. 10.
    Rino Y, Yamamoto Y, Wada N, Yukawa N, Murakami H, Tamagawa H, et al. Changes in vitamin D after gastrectomy. Gastric Cancer. 2007;10:228–33.CrossRefGoogle Scholar
  11. 11.
    Heaney RP. Health is better at serum 25(OH)D above 30 ng/mL. J Steroid Biochem Mol Biol. 2013;136:224–8.CrossRefGoogle Scholar
  12. 12.
    Qu X, Huang X, Jin F, Wang H, Hao Y, Tang T, et al. Bone mineral density and all-cause, cardiovascular and stroke mortality: a meta-analysis of prospective cohort studies. Int J Cardiol. 2013;166:385–93.CrossRefGoogle Scholar
  13. 13.
    Nakamura M, Ishiguro A, Muranaka T, Fukushima H, Yuki S, Ono K, et al. A prospective observational study on effect of short-term periodic steroid premedication on bone metabolism in gastrointestinal cancer (ESPRESSO-01). Oncologist. 2017;22:592–600.CrossRefGoogle Scholar
  14. 14.
    Baek KH, Jeon HM, Lee SS, Lim DJ, Oh KW, Lee WY, et al. Short-term changes in bone and mineral metabolism following gastrectomy in gastric cancer patients. Bone. 2008;42:61–7.CrossRefGoogle Scholar
  15. 15.
    Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:1137–41.CrossRefGoogle Scholar
  16. 16.
    Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25:2359–81.CrossRefGoogle Scholar
  17. 17.
    Rino Y, Yukawa N, Yamamoto N, Ohshima T, Sato T, Tamagawa H, et al. Self-defensive response to bone disorder after gastric cancer surgery. Clin Exp Med Sci. 2014;2:1–10.CrossRefGoogle Scholar
  18. 18.
    Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl. 2013;48:452–8.CrossRefGoogle Scholar
  19. 19.
    Kin K, Kushida K, Yamazaki K, Okamoto S, Inoue T. Bone mineral density of the spine in normal Japanese subjects using dual-energy X-ray absorptiometry: effect of obesity and menopausal status. Calcified Tissue Int. 1991;49:101–6.CrossRefGoogle Scholar
  20. 20.
    Riggs BL, Wahner HW, Dunn WL, Mazess RB, Offord KP, Melton LJ 3rd. Differential changes in bone mineral density of the appendicular and axial skeleton with aging: relationship to spinal osteoporosis. J Clin Investigation. 1981;67:328–35.CrossRefGoogle Scholar
  21. 21.
    Atsumi Y, Rino Y, Sato T, Cho H, Yoshikawa T, Yamamoto N, et al. Effectiveness of alendronate for bone disorder after gastrectomy for gastric cancer. Asian J Surg Asian Surg Assoc. 2017;40:470–4.CrossRefGoogle Scholar
  22. 22.
    Rino Y, Imada T, Yamamoto Y, Takahashi M, Amano T, Takanashi Y. The efficacy of 1 alpha hydroxy vitamin D3 treatment of the metabolic bone disorder in patients who underwent gastrectomy for gastric cancer. Hepato-gastroenterology. 2000;47:1498–500.Google Scholar
  23. 23.
    Kanis JA, on behalf of the WHO Scientific Group. Assessment of osteoporosis at the primary health care level. WHO Collaborating Centre for Metabolic Bone Diseases. In: WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield. 2007.Google Scholar
  24. 24.
    Rino Y. Clinical study of the relationship between a metabolic bone disorder and an amount of daily food intake. Yokohama Med J. 1996;47:25–9.Google Scholar
  25. 25.
    Karanicolas PJ, Graham D, Gonen M, Strong VE, Brennan MF, Coit DG. Quality of life after gastrectomy for adenocarcinoma: a prospective cohort study. Ann Surg. 2013;257:1039–46.CrossRefGoogle Scholar
  26. 26.
    Saeki H, Rino Y, Cho H, Sato T, Kawamoto M, Takanashi Y, et al. Evaluation of calorie intake according to age and sex in patients undergoing surgery for gastric cancer. Hepato-gastroenterology. 2008;55:795–8.Google Scholar
  27. 27.
    Yu W, Park KB, Chung HY, Kwon OK, Lee SS. Chronological changes of quality of life in long-term survivors after gastrectomy for gastric cancer. Cancer Res Treatment. 2016;48:1030–6.CrossRefGoogle Scholar
  28. 28.
    Rino Y, Oshima T, Yoshikawa T. Changes in fat-soluble vitamin levels after gastrectomy for gastric cancer. Surg Today. 2017;47:145–50.CrossRefGoogle Scholar
  29. 29.
    Bilezikian JP, Morishima A, Bell J, Grumbach MM. Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med. 1998;339:599–603.CrossRefGoogle Scholar
  30. 30.
    Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab. 1995;80:3689–98.Google Scholar
  31. 31.
    Vandenput L, Ohlsson C. Estrogens as regulators of bone health in men. Nat Rev Endocrinol. 2009;5:437–43.CrossRefGoogle Scholar

Copyright information

© The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2018

Authors and Affiliations

  1. 1.Department of SurgeryYokohama City UniversityYokohamaJapan
  2. 2.Department of SurgeryMiura City HospitalMiuraJapan
  3. 3.Department of Gastrointestinal SurgeryKanagawa Cancer CenterYokohamaJapan

Personalised recommendations